Lipocine Inc. (LPCN) financial statements (2021 and earlier)

Company profile

Business Address 675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, 84108
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1482127442845
Cash and cash equivalents10836202845
Short-term investments4 182124  
Receivables00300  
Other undisclosed current assets61300001
Total current assets:20212527452846
Noncurrent Assets
Property, plant and equipment0000000
Long-term investments and receivables    0  
Long-term investments    0  
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:20212527452846
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2121321
Accounts payable1110101
Accrued liabilities0011310
Debt33     
Estimated litigation liability  4    
Total current liabilities:5461321
Noncurrent Liabilities
Long-term debt and lease obligation47     
Long-term debt, excluding current maturities47     
Other undisclosed noncurrent liabilities5      
Total noncurrent liabilities:87     
Total liabilities:131161321
Stockholders' equity
Stockholders' equity attributable to parent691926422645
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0) 
Additional paid in capital1571481451311299593
Accumulated other comprehensive loss(0)(0)(0)(0)(0)  
Accumulated deficit(151)(138)(126)(105)(86)(68)(48)
Total stockholders' equity:691926422645
TOTAL LIABILITIES AND EQUITY:20212527452846

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:00     
Operating expenses(13)(12)(21)(19)(18)(20)(11)
Other operating income, net     00
Other undisclosed operating loss     (0)(0)
Operating loss:(13)(11)(21)(19)(18)(20)(11)
Nonoperating expense
(Other Nonoperating expense)
(0)(0)     
Other undisclosed income from continuing operations before equity method investments, income taxes0 00000
Loss from continuing operations before income taxes:(13)(12)(21)(19)(18)(20)(11)
Income tax expense (benefit)(0)(0)(0)(0)(0)(0)0
Net loss available to common stockholders, diluted:(13)(12)(21)(19)(18)(20)(11)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(13)(12)(21)(19)(18)(20)(11)
Comprehensive loss:(13)(12)(21)(19)(18)(20)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0000(0)  
Comprehensive loss, net of tax, attributable to parent:(13)(12)(21)(19)(18)(20)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: